Monte Rosa Therapeutics Inc GLUE:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 7:12 AM EDT
25.89quote price arrow up+0.22 (+0.86%)
Volume
100
Close
25.67quote price arrow up+1.15 (+4.69%)
Volume
124,670
52 week range
18.01 - 25.74

...

Loading . . .
  • Open24.95
  • Day High25.74
  • Day Low24.54
  • Prev Close25.67
  • 52 Week High25.74
  • 52 Week High Date08/02/21
  • 52 Week Low18.01
  • 52 Week Low Date07/14/21

Key Stats

  • Market Cap1.092B
  • Shares Out42.54M
  • 10 Day Average Volume0.16M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open24.95
  • Day High25.74
  • Day Low24.54
  • Prev Close25.67
  • 52 Week High25.74
  • 52 Week High Date08/02/21
  • 52 Week Low18.01
  • 52 Week Low Date07/14/21
  • Market Cap1.092B
  • Shares Out42.54M
  • 10 Day Average Volume0.16M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-0.99
  • P/E (TTM)-26.04
  • Fwd P/E (NTM)-15.25
  • EBITDA (MRQ)-34.481M
  • ROE (MRQ)-
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Monte Rosa Therapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

Profile

MORE
Monte Rosa Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops a protein degradation platform, called QuEEN, that enables it to identify protein targets and molecular glue degrader (MGD), product candidates that are designed to eliminate therapeutically relevant proteins. It...
Alexander Mayweg Ph.D.
Chairman
Markus Warmuth M.D.
Chief Executive Officer
Ajim Tamboli
Chief Financial Officer
Address
645 Summer Street, Suite 102
Boston, MA
02210
United States